TickerFacts.

Compare

Zai Lab Ltd vs Nature's Sunshine Products Inc vs Travere Therapeutics, Inc. vs BridgeBio Pharma, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearZai Lab Ltd
ZLAB		Nature's Sunshine Products Inc
NATR		Travere Therapeutics, Inc.
TVTX		BridgeBio Pharma, Inc.
BBIO
Year ended2025-12-312025-12-312025-12-312025-12-31
Revenue$457.18M$480.14M$490.73M$502.08M
Revenue growth (YoY)+15.0%+5.7%+110.5%+126.3%
Gross margin58.3% (computed)72.4%n/an/a
Operating margin-50.2%5.2%-12.8%-104.2%
Net margin-38.4%4.3%-5.2%-146.0%
Net income-$175.54M$20.45M-$25.55M-$732.94M
EPS (Diluted)-$0.16$1.06-$0.29-$3.78
Operating cash flow-$150.79M$35.32M$37.78M-$445.91M
Free cash flow-$158.89M$28.84Mn/a-$447.01M
Cash & equivalents$679.57M$93.89M$93.03M$570.12M
Total assets$1.17B$261.15M$605.19M$936.02M
Total liabilities$456.88M$99.59M$490.36M$3.01B
Shareholders' equity$715.50M$161.55M$114.83M-$2.09B
Return on year-end equity-24.5%12.7%-22.2%n/a
Shares outstanding1.11B17.51M90.92M194.77M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearZai Lab LtdNature's Sunshine Products IncTravere Therapeutics, Inc.BridgeBio Pharma, Inc.
Latest$457.18M
Ended 2025-12-31		$480.14M
Ended 2025-12-31		$490.73M
Ended 2025-12-31		$502.08M
Ended 2025-12-31
1 year earlier$397.61M
Ended 2024-12-31		$454.36M
Ended 2024-12-31		$233.18M
Ended 2024-12-31		$221.90M
Ended 2024-12-31
2 years earlier$266.72M
Ended 2023-12-31		$445.32M
Ended 2023-12-31		$145.24M
Ended 2023-12-31		$9.30M
Ended 2023-12-31
3 years earlier$212.67M
Ended 2022-12-31		$421.91M
Ended 2022-12-31		$109.46M
Ended 2022-12-31		$77.65M
Ended 2022-12-31
4 years earlier$144.10M
Ended 2021-12-31		$444.08M
Ended 2021-12-31		$131.84M
Ended 2021-12-31		$69.72M
Ended 2021-12-31